23.04.2014 • News • AstraZeneca • Camelot Management Consultants • Lean SCM

Andy Evans, Head of global SC planning, AstraZeneca about AstraZeneca's Lean SCM Journey

Andy Evans, Head of global SC planning, AstraZeneca
Andy Evans, Head of global SC planning, AstraZeneca

"Our Lean Supply Chain Visibility initiative reshaped our operations and supply chain management operating model with fundamental new global capabilities to realize end-to-end lean and agile supply chains and a step change in information systems."
Andy Evans, Head of global SC planning, AstraZeneca

AstraZeneca started its lean journey to respond to emerging cost pressure and higher market dynamics in managing global supply chains in the pharmaceutical industry. Following a clear lean vision for their entire supply chain organization, AstraZeneca established a demand-driven supply chain approach based upon lean planning methods, high end-to-end transparency, and strong process governance. The higher efficiency and responsiveness of their supply chain organization improved key figures such as working capital, lead-times, and asset utilization considerably. Furthermore, their lean supply chain strengthened their capability to provide highest customer service despite growing market uncertainties.

Learn more about Lean Supply Chain Planning, just visit www.leansupplychainplanning.com

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.